Download

Degrader-antibody conjugates (DACs) typically consist of a tumor-targeting antibody and a conjugated degrader payload, linked via a chemical linker. By integrating the degrader payload’s capacity to precisely degrade disease-causing proteins with the antibody’s tumor-targeting specificity, DACs emerge as an innovative and promising therapeutic modality for cancer treatment. Herein, we present the well-established DAC integrated platform developed by ICE Bioscience, which facilitates the characterization and evaluation of DACs from in vitro assays to in vivo studies.

Download

Antibody-drug conjugates (ADCs), combining the precision of antibodies with the potency of cytotoxic drugs, represent a promising anticancer therapy. However, current ADCs face significant challenges, including non-responsive cancers and rapid patient relapse, primarily due to tumor heterogeneity and drug resistance. To address these issues, dual-payload ADCs have emerged as a novel strategy, delivering two cytotoxic agents to enhance efficacy through synergistic effects, mitigate resistance, and offer flexible dosing. Despite their potential, the development of dual-payload ADCs remains complex. Cell panel-based studies and drug-resistant cell lines provide powerful tools to explore effective dual-payload ADCs by evaluating drug combination synergies and elucidating resistance mechanisms.

Download

Covalent inhibitors, with irreversible target engagement, have become pivotal in drug discovery. Liquid chromatography-high-resolution mass spectrometry (LC-HRMS) is uniquely suited for high-throughput screening of these molecules, enabling label-free detection of native proteins and covalent adducts, precise quantification of target engagement through exact mass analysis, rapid characterization of binding kinetics (e.g., kinact/KI values) via intact protein analysis, and further binding site identification by peptide mapping analysis.

Download

Voltage gated sodium channels are pivotal therapeutic targets implicated in a variety of disorders, including chronic pain, epilepsy, and cardiac arrhythmias. The discovery of modulators that selectively and effectively target specific sodium channel subtypes requires advanced screening methodologies capable of producing accurate and biologically relevant data. This report outlines a fully integrated in vitro platform designed to streamline and enhance the discovery of sodium channel modulators through a multi-step approach: 1). Preliminary Screening: State dependent assays to identify potent compounds with targeted activity; 2). Selectivity Profiling: Determination of isoform selectivity (Nav1.1–Nav1.8) and species-specific selectivity; 3). Secondary Screening: Use-dependent assays to provide biologically relevant insights into compound activity; 4). Primary Neuron-Based Assays: Evaluation of candidate compounds using dorsal root ganglion (DRG) neurons from mouse, rat, cynomolgus monkey and human models; 5). Safety Profiling: Comprehensive assessment of off-target liabilities using a safety panel. This Strategy enables the efficient identification and optimization of sodium channel modulators with superior specificity, efficacy, and safety profiles. By addressing critical challenges such as subtype selectivity and off-target effects, it facilitates the accelerated development of next-generation therapeutics targeting ion channels.